Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Up 3.5% – Here’s Why

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX)’s share price traded up 3.5% on Friday . The stock traded as high as $1.50 and last traded at $1.48. 95,132 shares changed hands during mid-day trading, a decline of 76% from the average session volume of 388,412 shares. The stock had previously closed at $1.43.

Analyst Ratings Changes

Separately, Maxim Group lowered their price objective on Theriva Biologics from $25.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th.

Theriva Biologics Stock Performance

Theriva Biologics (NYSEAMERICAN:TOVX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($6.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.25) by ($0.56).

Institutional Trading of Theriva Biologics

An institutional investor recently bought a new stake in Theriva Biologics stock. Anson Funds Management LP acquired a new stake in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned about 6.13% of Theriva Biologics at the end of the most recent quarter. Institutional investors own 6.17% of the company’s stock.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.